Frank Weinholt, MD
Psychiatry · West Monroe, LANPI 1326126442
Payments from drug & device makers
Across 734 payments — averaging $39.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$16K
- Acadia Pharmaceuticals Inc$4K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- AbbVie$929
- plus $4K from 14 others
What the payments were for
- Speaking & faculty fees$14,40049%
- Travel & lodging$8333%
- Food & beverage$13,87447%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 35 | $16,073 |
| Acadia Pharmaceuticals Inc | 324 | $3,805 |
| Neurocrine Biosciences, Inc. | 58 | $2,058 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 50 | $1,294 |
| Alkermes, Inc. | 41 | $1,204 |
| AbbVie(2 entities) | 71 | $929 |
| Otsuka America Pharmaceutical, Inc. | 35 | $840 |
| Vanda Pharmaceuticals Inc. | 33 | $758 |
| Johnson & Johnson | 15 | $470 |
| Axsome Therapeutics, Inc. | 4 | $381 |
| Teva Pharmaceuticals USA, Inc. | 11 | $339 |
| Lundbeck LLC | 19 | $337 |
| E.r. Squibb & Sons, L.L.C. | 11 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $214 |
| Sunovion Pharmaceuticals Inc. | 6 | $98 |
| Shire North American Group Inc | 5 | $77 |
| Eisai Inc. | 1 | $23 |
| Indivior Inc. | 1 | $19 |
| Merck | 1 | $15 |
| Alpha Cognition USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,217 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 45 | $225,035 |
| VraylarCariprazine Hcl | 26 | $52,498 |
| CaplytaLumateperone Tosylate | 31 | $47,847 |
| RexultiBrexpiprazole | 27 | $41,061 |
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $27,866 |
| TrintellixVortioxetine Hydrobromide | 30 | $16,567 |
| Rivastigmine | 108 | $15,965 |
| FetzimaLevomilnacipran Hcl | 12 | $11,350 |
| EliquisApixaban | 17 | $8,978 |
| Aripiprazole | 39 | $7,559 |
| Memantine Hcl | 119 | $4,757 |
| Ziprasidone Hcl | 47 | $3,649 |
| Pimozide | 67 | $2,923 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 52 | $2,738 |
| Lamotrigine | 210 | $2,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $3,805 | $225,03545 claims |
| AbbVieVraylar, Fetzima | $929 | $63,84838 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,294 | $47,84731 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $840 | $41,06127 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $16,073 | $27,86623 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $214 | $16,56730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in West Monroe
- Kashinath YadalamLake Charles$3.8M
- Guy BrannonShreveport$1.4M
- Patrick HayesLake Charles$853K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Aruna GullapalliMonroe$287K
- Roger BrownMandeville$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.